Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib Combined With GemOx in Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT07279584Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Ruijin Hospital. Primary endpoint: Overall Response Rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07279584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279584.